Post-Traumatic Stress Disorder (PTSD)
Post-traumatic stress disorder (PTSD) is a psychiatric condition that may develop in individuals who have experienced or witnessed a traumatic event, such as combat, sexual assault, accidents, natural disasters, or severe threats to life.1American Psychiatric Association. (2022). Diagnostic and Statistical Manual of Mental Disorders (5th ed., text rev.). Characterized by persistent psychological and physiological distress, PTSD disrupts emotional regulation, memory processing, and nervous system functioning.
PTSD affects approximately 7.8% of U.S. adults at some point in their lives, with women nearly twice as likely as men to develop the disorder. Prevalence varies significantly across cultures, trauma types, and socioeconomic factors.2
Overview & Historical Context
While PTSD was formally recognized as a distinct diagnosis in the DSM-III (1980) following advocacy by Vietnam War veterans and survivors of interpersonal violence, clinical descriptions of trauma-related symptoms date back to ancient Greece, Roman warfare accounts, and 19th-century "railway spine" and "shell shock" diagnoses.3 Modern neuroscience reveals that PTSD involves dysregulation in the amygdala (fear processing), hippocampus (memory consolidation), and prefrontal cortex (executive control), leading to exaggerated threat detection and impaired fear extinction.
Core Symptoms & Diagnostic Criteria
According to the DSM-5-TR, PTSD symptomatology is organized into four clusters that must persist for >1 month and cause significant functional impairment:4
- Intrusion Symptoms: Recurrent distressing memories, nightmares, flashbacks, or intense psychological/physiological reactivity to trauma reminders.
- Avoidance: Persistent efforts to avoid trauma-related thoughts, feelings, conversations, places, or activities.
- Negative Alterations in Cognition & Mood: Inability to recall key aspects of the trauma, persistent negative beliefs about self/world, distorted blame, diminished interest, detachment, or persistent inability to experience positive emotions.
- Alterations in Arousal & Reactivity: Irritability, reckless behavior, hypervigilance, exaggerated startle response, concentration difficulties, or sleep disturbance.
Etiology & Risk Factors
PTSD development follows a biopsychosocial model involving multiple interacting factors:
- Trauma Exposure: Severity, duration, interpersonal nature (e.g., assault vs. accident), and perceived life threat significantly influence risk.5
- Biological Vulnerability: Genetic predispositions (e.g., FKBP5 polymorphisms), reduced hippocampal volume, and HPA axis dysregulation.
- Psychological Factors: Pre-existing anxiety/depression, maladaptive coping strategies, and early childhood trauma (ACEs).
- Social & Environmental Context: Lack of post-trauma support, socioeconomic disadvantage, cultural stigma around mental health, and repeated trauma exposure.
Assessment & Differential Diagnosis
Diagnosis requires a structured clinical interview aligned with DSM-5-TR or ICD-11 criteria. Clinicians commonly use validated tools such as the PCL-5 (PTSD Checklist for DSM-5), CAPS-5 (Clinician-Administered PTSD Scale), or IES-R (Impact of Event Scale-Revised).6 Differential diagnosis must rule out acute stress disorder, adjustment disorders, depression, anxiety disorders, complex PTSD (C-PTSD, per ICD-11), and substance-induced conditions.
This article provides educational information only and does not replace professional medical or psychological evaluation. If you or someone you know is experiencing trauma-related distress, please contact a licensed mental health provider or crisis hotline.
Evidence-Based Treatment Approaches
Current guidelines recommend trauma-focused psychotherapies as first-line interventions, often combined with pharmacotherapy for moderate-to-severe cases:7
Psychotherapy
- Cognitive Processing Therapy (CPT): Restructures maladaptive beliefs related to the trauma.
- Prolonged Exposure (PE): Gradual, controlled exposure to trauma memories and avoided situations to promote fear extinction.
- Eye Movement Desensitization & Reprocessing (EMDR): Bilateral stimulation paired with trauma recall to facilitate adaptive information processing.
- Somatic & Body-Based Therapies: Focus on nervous system regulation and trauma stored in physiological patterns.
Pharmacotherapy
Selective serotonin reuptake inhibitors (SSRIs) such as sertraline and paroxetine are FDA-approved for PTSD. SNRIs (venlafaxine) and prazosin (for trauma-related nightmares) are commonly used off-label. Benzodiazepines are generally discouraged due to lack of efficacy and potential for worsening outcomes.8
Emerging & Adjunctive Interventions
Research is exploring ketamine-assisted therapy, MDMA-assisted psychotherapy (FDA breakthrough therapy designation), mindfulness-based stress reduction (MBSR), neurofeedback, and virtual reality exposure therapy.
Prognosis & Recovery Trajectory
PTSD follows a heterogeneous course. Approximately 50-70% of individuals experience significant symptom reduction within 3-6 months of trauma, while 20-30% develop chronic PTSD. Recovery is strongly predicted by early intervention, social support, access to trauma-informed care, and absence of comorbid substance use. Neuroplasticity remains intact throughout adulthood, meaning the brain can rewire trauma responses with consistent therapeutic intervention.9
References & Further Reading
- 1 American Psychiatric Association. (2022). Diagnostic and Statistical Manual of Mental Disorders (5th ed., text rev.). Arlington, VA: APA Publishing.
- 2 Kessler, R. C., et al. (2017). Trauma exposures and PTSD in U.S. adults. American Journal of Psychiatry, 174(1), 87-96.
- 3 van der Kolk, B. A. (2014). The Body Keeps the Score: Brain, Mind, and Body in the Healing of Trauma. Viking.
- 4 Brewin, C. R., et al. (2017). Diagnostic thresholds for PTSD. British Journal of Psychiatry, 210(5), 276-282.
- 5 Pietrzak, R. H., et al. (2011). Prevalence of DSM-IV PTSD in the general population. Journal of Traumatic Stress, 24(3), 311-318.
- 6 Weathers, F. W., et al. (2018). The Clinician-Administered PTSD Scale for DSM-5 (CAPS-5). Psychological Assessment, 30(12), 1353-1358.
- 7 National Center for PTSD. (2023). Treatment Guidelines for PTSD. U.S. Department of Veterans Affairs.
- 8 Stein, M. B., et al. (2021). Pharmacotherapy for PTSD: A systematic review. The Lancet Psychiatry, 8(5), 412-424.
- 9 National Institute of Mental Health. (2023). Trauma and PTSD. Bethesda, MD: NIMH.
Report an issue? If you notice outdated information, missing citations, or cultural inaccuracies, please submit a correction request to our editorial team.